UK Continuous, Integrated Biologics Manufacturing Project

As biopharma moves to the business mainstream, the industry will increasingly need to find new ways

to maintain competitiveness by ensuring affordability, quality, and delivery performance. Continuous

processes have been proposed as a solution as they are scalable, offer higher productivity with reduced

running times and materials usage, and require smaller footprint and less capital intense facilities. The

project brings together five leading biopharmaceutical companies with UK Operations, process

technology suppliers and a Catapult centre to develop an automated continuous biologics purification

unit for more efficient manufacture of a wide range of biologic drugs. The new unit will consist of

integrated, multiple operations running concurrently.